Angiotensin II cyclic analogs as tools to investigate AT1R biased signaling mechanisms
David St-Pierre, J\'er\^ome Cabana, Brian J. Holleran, \'Elie, Besserer-Offroy, Emanuel Escher, Ga\'etan Guillemette, Pierre Lavigne, and, Richard Leduc

TL;DR
This study investigates how cyclic analogs of angiotensin II influence biased signaling at the AT1 receptor, revealing that ligand conformation constraints can modulate receptor pathway activation and aid drug design.
Contribution
The paper introduces cyclic analogs of angiotensin II and demonstrates their ability to selectively bias AT1 receptor signaling pathways, advancing understanding of ligand-receptor conformational dynamics.
Findings
[Sar1Hcy3,5]AngII exhibits broad pathway activation except Gq.
Molecular dynamics show increased energy barrier for Gq activation with cyclic analogs.
Cyclic constraints on ligands can enhance biased agonism at GPCRs.
Abstract
G protein coupled receptors (GPCRs) produce pleiotropic effects by their capacity to engage numerous signaling pathways once activated. Functional selectivity (also called biased signaling), where specific compounds can bring GPCRs to adopt conformations that enable selective receptor coupling to distinct signaling pathways, continues to be significantly investigated. However, an important but often overlooked aspect of functional selectivity is the capability of ligands such as angiotensin II (AngII) to adopt specific conformations that may preferentially bind to selective GPCRs structures. Understanding both receptor and ligand conformation is of the utmost importance for the design of new drugs targeting GPCRs. In this study, we examined the properties of AngII cyclic analogs to impart biased agonism on the angiotensin type 1 receptor (AT1R). Positions 3 and 5 of AngII were…
Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
